NeuroPace initiated with a Buy at UBS

UBS analyst Priya Sachdeva initiated coverage of NeuroPace (NPCE) with a Buy rating and $17 price target The firm views NeuroPace’s responsive neuromodulation system technology as providing a “differentiated, and clinically proven interventional solution to address the vastly undertreated and underpenetrated” drug resistant epilepsy market. The shares should see multiple expansion over the next twelve months as the company is “on the verge” of addressable market expanding catalysts in the second half of 2025 that should drive a growth inflection, the analyst tells investors in a research note.